Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of drug development—outpacing the growth of the wider pharmaceuticals landscape, and accounting for an increasingly large proportion of novel drugs hitting the market. By 2026, orphans will make up a fifth of all prescription drug sales, and almost a third of the global drug pipeline’s value.
Our Orphan Drug Report 2022 draws on Evaluate’s deep knowledge of the sector to highlight the big issues in this increasingly competitive – and lucrative space.
Our Orphan Drug Report 2022: Niche No Longer is now available for download.
